Pfizer (NYSE:PFE) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Pfizer (NYSE:PFE – Get Rating) in a report issued on Thursday. The brokerage issued a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on PFE. The Goldman Sachs Group raised Pfizer from a neutral rating to a buy rating and upped their price target for the company from $47.00 to $60.00 in a report on Tuesday, December 13th. UBS Group set a $45.00 price target on Pfizer in a report on Tuesday, March 14th. JPMorgan Chase & Co. set a $45.00 price target on Pfizer in a report on Monday, February 27th. Morgan Stanley reduced their price objective on Pfizer from $53.00 to $45.00 and set an equal weight rating for the company in a research note on Wednesday, February 1st. Finally, Atlantic Securities reduced their price objective on Pfizer from $50.00 to $46.00 and set a neutral rating for the company in a research note on Wednesday, February 1st. Nine equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Pfizer presently has a consensus rating of Hold and a consensus target price of $50.38.

Pfizer Price Performance

Pfizer stock opened at $40.10 on Thursday. Pfizer has a 1 year low of $39.23 and a 1 year high of $56.32. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.00 and a current ratio of 1.22. The company’s fifty day moving average price is $43.26 and its 200 day moving average price is $46.03. The stock has a market capitalization of $225.33 billion, a P/E ratio of 7.32, a P/E/G ratio of 1.35 and a beta of 0.64.

Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.11. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The firm had revenue of $24.30 billion for the quarter, compared to analyst estimates of $24.40 billion. During the same period in the previous year, the firm earned $1.08 EPS. Pfizer’s revenue was up 1.9% on a year-over-year basis. As a group, equities research analysts anticipate that Pfizer will post 3.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Several large investors have recently modified their holdings of PFE. RB Capital Management LLC raised its stake in shares of Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. raised its position in Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after acquiring an additional 400 shares in the last quarter. United Bank raised its position in Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after acquiring an additional 290 shares in the last quarter. Ergoteles LLC raised its position in Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after acquiring an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp raised its position in Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after acquiring an additional 79,887 shares in the last quarter. Hedge funds and other institutional investors own 67.62% of the company’s stock.

About Pfizer

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.